go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

Shire Pharmaceuticals Ireland Limited

Shire Pharmaceuticals Ireland Limited
5 Riverwalk, Citywest Business Campus, Dublin 24, Ireland,
Telephone: +353 1 429 7700
Fax: +353 1 429 7701
Medical Information Direct Line: 1 800 818 016
Medical Information e-mail: MedInfoIE@shire.com
Customer Care direct line: +44 (0)1256 894 107
Summary of Product Characteristics last updated on medicines.ie: 26/03/2012
SPC Resolor 1 mg film-coated tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 26/03/2012 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
Date of revision of text on the SPC:   01-Mar-2012
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company



Change to section 4.2 – Posology and method of administration;

 

Patients with hepatic impairment: Patients with severe hepatic impairment (Child-Pugh class C) start with 1 mg once daily which may be increased to 2 mg if required to improve efficacy and if the 1 mg dose is well tolerated (see sections 4.4 and 5.2). The dose for patients with severe hepatic impairment (Child‑Pugh class C) is 1 mg once daily (see sections 4.4 and 5.2). No dose adjustment is required for patients with mild to moderate hepatic impairment.

 

 

Change to section 4.4 – Special warnings and precautions for use;

 

Renal excretion is the main route of elimination of prucalopride (see section 5.2). A dose of 1 mg is recommended in subjects with severe renal impairment (see section 4.2).

 

Caution should be exercised when prescribing Resolor to patients with severe hepatic impairment (Child-Pugh class C) due to limited data in patients with severe hepatic impairment (see section 4.2).

 

Patients with severe and clinically unstable concomitant disease (e.g. liver, cardiovascular or lung disease, neurological or psychiatric disorders, cancer or AIDS and other endocrine disorders) have not been studied. Caution should be exercised when prescribing Resolor to patients with these conditions. In particular Resolor should be used with caution in patients with a history of arrhythmias or ischaemic cardiovascular disease.

 

In case of severe diarrhoea, the efficacy of oral contraceptives may be reduced and the use of an additional contraceptive method is recommended to prevent possible failure of oral contraception (see the prescribing information of the oral contraceptive).

 

It is unlikely that hepatic impairment will affect prucalopride metabolism and exposure in man to a clinically relevant extent. No data are available in patients with mild, moderate or severe hepatic impairment, and therefore a lower dose is recommended for patients with severe hepatic impairment (see section 4.2).Men: The safety and efficacy of Resolor for use in men has not been established in controlled clinical trials therefore Resolor is not recommended for use in men until further data becomes available.

 

 

Change to section 4.5 – Interaction with other medicinal products and other forms of interaction;

 

In vitro data indicate that pPrucalopride has a low pharmacokinetic interaction potential. It is extensively excreted unchanged in urine (approximately 60% of the dose), and in vitro metabolism is very slow. Although 8 different metabolites are known, the most abundant of these, the carboxylic acid product of side-chain oxidative O-demethylation, represents less than 4% of the dose.

  

Prucalopride did not inhibit specific CYP450 activities in in vitro studies in human liver microsomes at therapeutically relevant concentrations. 

 

Although prucalopride may be a weak substrate for P-glycoprotein (P‑gp), it is not an inhibitor of P-gp at clinically relevant concentrations.

 

Effects of prucalopride on pharmacokinetics of other drugs  

 

A 30% increase in plasma concentrations of erythromycin was found during prucalopride co-administration. The mechanism for this interaction is not clear.

 

Prucalopride had no clinically relevant effects on the pharmacokinetics of warfarin, digoxin, alcohol, paroxetine or oral contraceptives.

 

Effects of other drugs on pharmacokinetics of prucalopride

 

Ketoconazole (200 mg b.i.d.), a potent inhibitor of CYP3A4 and of P‑gp, increased the area under the curve (AUC) of systemic exposure to prucalopride by approximately 40%. This effect is too small to be clinically relevant. and is likely attributable to inhibition of P-gp mediated renal transport. Interactions of similar magnitude as observed with ketoconazole may also occur be expected with other potent inhibitors of P‑gp such as verapamil, cyclosporine A and quinidine.

 

Therapeutic doses of probenecid, cimetidine, erythromycin and paroxetine did not affect the pharmacokinetics of prucalopride.

 

Prucalopride is likely also secreted via another renal transporter(s). Inhibition of all transporters involved in the active secretion of prucalopride (including P‑gp) may theoretically increase the exposure by up to 75%.

 

Studies in healthy subjects showed that there were no clinically relevant effects of prucalopride on the pharmacokinetics of warfarin, digoxin, alcohol, and paroxetine and oral contraceptives. A 30% increase in the plasma concentrations of erythromycin was found during prucalopride co-treatment. The mechanism for this interaction is not fully known, but the available data support that this is the consequence of the high intrinsic variability in erythromycin kinetics, rather than a direct effect of prucalopride.

 

Resolor should be used with caution in patients receiving concomitant drugs known to cause QTc prolongation.

 

Because of the mechanism of action, the use of atropine-like substances may reduce the 5‑HT4 receptor mediated effects of prucalopride.

 

Effect of food

 

Interactions with food have not been observed.

 

 

Change to section 4.8 – Undesirable effects;

 

The following adverse reactions were reported in controlled clinical studies at the recommended dose of 2 mg with frequencies corresponding to Very common (≥ 1/10), Common (≥ 1/100 to < 1/10), Uncommon (≥> 1/1,000 to < 1/100), Rare (≥> 1/10,000 to < 1/1,000) and Very rare (≤< 1/10,000).

 

 

Change to section 5.1 – Pharmacodynamic properties;

 

Mechanism of action

Prucalopride is a dihydrobenzofurancarboxamide with enterokinetic gastrointestinal prokinetic activities.  Prucalopride is a selective, high affinity serotonin (5‑HT4) receptor agonist, which is likely to explain its enterokinetic prokinetic effects.

 

 

Change to section 5.2 – Pharmacokinetic properties;

 

Hepatic impairment

Non-renal elimination contributes to about 35% of total elimination. In a small pharmacokinetic study, the Cmax and AUC of prucalopride were, on average, 10-20% higher in patients with moderate to severe hepatic impairment compared with healthy subjects (see sections 4.2 and 4.4).

, and hepatic impairment is unlikely to affect the pharmacokinetics of prucalopride to a clinically relevant extent (see section 4.2 and 4.4)

 

Updated on 27/02/2012 and displayed until 26/03/2012
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.3 - Contraindications
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   01-Feb-2012
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company

2. Qualitative and quantitative composition

For thea full list of excipients, see section 6.1.


4.3 Contraindications

-                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.6 Fertility, pregnancy and lactation

Breast-feeding

Lactation

 


5.1 Pharmacodynamic properties

Clinical experience

The efficacy of prucalopride was established in three multicentre, randomised, double‑blind, 12‑week placebo‑controlled studies in subjects with chronic constipation (n=1,279 on prucalopride, 1,124 females, 155 males). The prucalopride doses studied in each of these three studies included 2 mg and 4 mg once daily. The primary efficacy endpoint was the proportion (%) of subjects that reached normalisation of bowel movements defined as an average of three or more spontaneous, complete bowel movements (SCBM) per week over the 12‑week treatment period. For the population targeted in this label, the results are the following: The proportion of female patients in whom laxatives fail to provide adequate relief (target population) treated with the recommended dose of 2 mg prucalopride (n=458) that reached an average of ≥ 3 SCBM per week was 31.0% (week 4) and 24.7% (week 12), versus 8.6% (week 4) and 9.2% (week 12) on placebo. A clinically meaningful improvement of ≥ 1 SCBM per week, the most important secondary efficacy endpoint, was achieved in 51.0% (week 4) and 44.2% (week 12) treated with 2 mg prucalopride versus 21.7% (week 4) and 22.6% (week 12) of placebo patients. Also for the target population prucalopride proved significantly superior (p<0.001) to placebo at the primary endpoint.

 

Both doses were statistically superior (p<0.001) to placebo at the primary endpoint in each of the three studies, with no incremental benefit of the 4 mg over the 2 mg dose. The proportion of patients treated with the recommended dose of 2 mg prucalopride that reached an average of ≥ 3 SCBM per week was 27.8% (week 4) and 23.6% (week 12), versus 10.5% (week 4) and 11.3% (week 12) on placebo. A clinically meaningful improvement of ≥ 1 SCBM per week, the most important secondary efficacy endpoint, was achieved in 48.1% (week 4) and 43.1% (week 12) of patients treated with 2 mg prucalopride versus 23.4% (week 4) and 24.6% (week 12) of placebo patients.

 

In all three studies, treatment with prucalopride also resulted in significant improvements in a validated and disease specific set of symptom measures (PAC SYM), including abdominal, stool and rectal symptoms, determined at week 4 and week 12. A significant benefit on a number of Quality of Life measures, such as degree of satisfaction with treatment and with bowel habits, physical and psychosocial discomfort and worries and concerns, was also observed at both the 4 and 12 week assessment time points.

 

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

15 October 20/10/09


10. DATE OF REVISION OF THE TEXT 

 

Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http://www.emaemea.europa.eu/.

Updated on 06/02/2012 and displayed until 27/02/2012
Reasons for adding or updating:
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Date of revision of text on the SPC:   01-Jan-2012
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company



In section 4.5 (Interaction) the following was added:

Studies in healthy subjects showed that there were no clinically relevant effects of prucalopride on the pharmacokinetics of warfarin, digoxin, alcohol, paroxetine or oral contraceptives.

Updated on 07/11/2011 and displayed until 06/02/2012
Reasons for adding or updating:
  • Change to section 6.3 - Shelf life
Date of revision of text on the SPC:   01-Oct-2011
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company

Change in shelf life from three to four years.
Updated on 11/05/2011 and displayed until 07/11/2011
Reasons for adding or updating:
  • New SPC for medicines.ie
Date of revision of text on the SPC:  
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company

None provided

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Prucalopride Succinate

Versions

 
26/03/2012 to Current
27/02/2012 to 26/03/2012
06/02/2012 to 27/02/2012
07/11/2011 to 06/02/2012
11/05/2011 to 07/11/2011
  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo